1871 Inhibition of mTOR in combination with chemotherapy and angiogenic blockade shows activity in metaplastic breast cancer, an aggressive, chemo-refractory subtype of triple-negative breast cancer (TNBC). (September 2015) - Basho, R.; Janku, F.; Helgason, T.; Gilcrease, M.; Booser, D.; Karp, D.; Meric-Bernstam, F.; Wheler, J.; Valero, V.; Albarracin, C.; Litton, J.; Chavez-MacGregor, M.; et al.